All In Biotech

Drug Trial Radar · NCT03945292

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]

Last checked: Nov 19, 2026Latest source record: Nov 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Aug 7, 2019

Primary completion

Nov 8, 2021

Study completion Sep 18, 2023

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).

Conditions

  • Alpha 1-Antitrypsin Deficiency

Interventions

  • Fazisiran InjectionDrug

    solution for subcutaneous (sc) injection

  • PlaceboOther

    sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Serum Z-Alpha-1 Antitrypsin (Z-AAT) at Week 16Time frame: Baseline, Week 16 (+/- 2 weeks)

Locations

21 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site 5

    Birmingham, Alabama

  • Research Site 9

    Phoenix, Arizona

  • Research Site 14

    La Jolla, California

  • Research Site 17

    Los Angeles, California

  • Research Site 11

    Sacramento, California

  • Research Site 15

    San Francisco, California

  • Research Site 13

    Stanford, California

  • Research Site 2

    Gainesville, Florida

  • Research Site 7

    Indianapolis, Indiana

  • Research Site 3

    Iowa City, Iowa

  • Research Site 10

    St Louis, Missouri

  • Research Site 12

    New York, New York

  • Research Site 1

    Charleston, South Carolina

  • Research Site 4

    Nashville, Tennessee

  • Research Site 19

    Houston, Texas

  • Research Site 16

    Salt Lake City, Utah

  • Research Site 27

    Aachen, Germany

  • Research Site 22

    Pavia, Italy

  • Research Site 23

    Leiden, Netherlands

  • Research Site 24

    Funchal, Portugal

  • Research Site 20

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.